

The effect of Neuragen® on neuropathic pain: Double-blind, placebo-controlled clinical trial

Submission date 04/06/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 09/06/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 16/08/2011	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Li Li

Contact details
Department of Kinesiology
Louisiana State University
Baton Rouge
United States of America
70803

Additional identifiers

Study information

Scientific Title

Study objectives
Neuragen® reduces neuropathic pain more than placebo.

Ethics approval required
Old ethics approval format

Ethics approval(s)

Institutional Review Board, Louisiana State University. Date of approval: 09/28/2007 (ref: 2754)

Study design

Double-blind, randomised, placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Peripheral neuropathy

Interventions

Topical application of Neuragen® vs placebo. Neuragen®/placebo is applied once each in random order and in a double-blind fashion. The applications are at least one week apart from each other. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours.

Total duration of follow-up: 8 hours after each application

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Foot sole pain on 11-point numerical pain scale, measured 30 minutes before and after the Neuragen®/placebo application, and tracked every hour for 8 hours.

Key secondary outcome(s)

Duration of pain reduction. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours.

Completion date

27/09/2008

Eligibility**Key inclusion criteria**

1. Both males and females, over 21
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3-8 on a 0-10 visual pain scale
4. Does not have mental and communication impairments

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment

Date of first enrolment

01/10/2007

Date of final enrolment

27/09/2008

Locations**Countries of recruitment**

United States of America

Study participating centre

Department of Kinesiology

Baton Rouge

United States of America

70803

Sponsor information**Organisation**

Origin BioMed, Inc. (Canada)

ROR

<https://ror.org/008mcnd42>

Funder(s)**Funder type**

Industry

Funder Name

Origin BioMed, Inc. (Canada)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration